| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Cellular and Structural Biology [A. B., J. Y., L-Z. S.] and Surgery [S. N. M.], University of Texas Health Science Center, San Antonio, Texas 78229, and Departmento de Biologia Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, D.F., 04510, Mexico [F. L-C., J. L. M., V. M.]
We have demonstrated previously that ectopic expression of a soluble betaglycan, also known as transforming growth factor (TGF) ß type III receptor, can suppress the malignant properties of human carcinoma cells by antagonizing the tumor-promoting activity of TGF-ß (A. Bandyopadhyay et al., Cancer Res., 59: 5041–5046, 1999). In the current study, we investigated the potential therapeutic utility of a recombinant preparation of human and rat soluble betaglycan (sBG). Purified recombinant human sBG showed similar properties to its rat counterpart (M. M. Vilchis-Landeros et al., Biochem J., 355: 215–222, 2001). It bound TGF-ß with high affinity and isoform selectivity and neutralized the activity of TGF-ß1 in two bioassays. Peritumoral (50 µg/tumor, twice a week) or i.p. (100 µg/animal, every alternate day) injection of sBG into human breast carcinoma MDA-MB-231 xenograft-bearing athymic nude mice significantly inhibited the tumor growth. The administration of sBG also reduced metastatic incidence and colonies in the lungs. The tumor-inhibitory activity of sBG was found to be associated with the inhibition of angiogenesis. Systemic sBG treatment significantly reduced tumor microvessel density detected with histological analyses and CD-31 immunostainings, as well as tumor blood volume measured with hemoglobin content. In an in vitro angiogenesis assay, treatment with the recombinant sBG significantly reduced the ability of human dermal microvascular endothelial cells to form a capillary tube-like structure on Matrigel. These findings support the conclusion that sBG treatment suppresses tumor growth and metastasis, at least in part by inhibiting angiogenesis. As such, it could be a useful therapeutic agent to antagonize the tumor-promoting activity of TGF-ß.
This article has been cited by other articles:
|
|
 |
|
  T. Fujita, K. Teramoto, Y. Ozaki, J. Hanaoka, N. Tezuka, Y. Itoh, T. Asai, S. Fujino, K. Kontani, and K. Ogasawara Inhibition of Transforming Growth Factor-{beta}-Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types Cancer Res., June 15, 2009; 69(12): 5142 - 5150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Nam, M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, et al. An Anti-Transforming Growth Factor {beta} Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments Cancer Res., May 15, 2008; 68(10): 3835 - 3843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al. A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection Cancer Res., March 1, 2007; 67(5): 2351 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Turley, E. C. Finger, N. Hempel, T. How, T. A. Fields, and G. C. Blobe The Type III Transforming Growth Factor-{beta} Receptor as a Novel Tumor Suppressor Gene in Prostate Cancer Cancer Res., February 1, 2007; 67(3): 1090 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Juarez, M. M. Vilchis-Landeros, J. Ponce-Coria, V. Mendoza, R. Hernandez-Pando, N. A. Bobadilla, and F. Lopez-Casillas Soluble betaglycan reduces renal damage progression in db/db mice Am J Physiol Renal Physiol, January 1, 2007; 292(1): F321 - F329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Zhao and F. M. Hoffmann Inhibition of Transforming Growth Factor-beta1-induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARA Mol. Biol. Cell, September 1, 2006; 17(9): 3819 - 3831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146. [Full Text] [PDF]
|
|
|
|
|
|
A. Bandyopadhyay, J. K. Agyin, L. Wang, Y. Tang, X. Lei, B. M. Story, J. E. Cornell, B. H. Pollock, G. R. Mundy, and L.-Z. Sun Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-{beta} Type I Receptor Kinase Inhibitor. Cancer Res., July 1, 2006; 66(13): 6714 - 6721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wiater, C. A. Harrison, K. A. Lewis, P. C. Gray, and W. W. Vale Identification of Distinct Inhibin and Transforming Growth Factor beta-binding Sites on Betaglycan: FUNCTIONAL SEPARATION OF BETAGLYCAN CO-RECEPTOR ACTIONS J. Biol. Chem., June 23, 2006; 281(25): 17011 - 17022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Nam, A. M. Suchar, M.-J. Kang, C. H. Stuelten, B. Tang, A. M. Michalowska, L. W. Fisher, N. S. Fedarko, A. Jain, J. Pinkas, et al. Bone Sialoprotein Mediates the Tumor Cell-Targeted Prometastatic Activity of Transforming Growth Factor {beta} in a Mouse Model of Breast Cancer. Cancer Res., June 15, 2006; 66(12): 6327 - 6335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Meurer, L. Tihaa, B. Lahme, A. M. Gressner, and R. Weiskirchen Identification of Endoglin in Rat Hepatic Stellate Cells: NEW INSIGHTS INTO TRANSFORMING GROWTH FACTOR {beta} RECEPTOR SIGNALING J. Biol. Chem., January 28, 2005; 280(4): 3078 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Muraoka-Cook, N. Dumont, and C. L. Arteaga Dual Role of Transforming Growth Factor {beta} in Mammary Tumorigenesis and Metastatic Progression Clin. Cancer Res., January 15, 2005; 11(2): 937s - 943s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.S. Prime, M. Pring, M. Davies, and I.C. Paterson TGF-{beta} SIGNAL TRANSDUCTION IN ORO-FACIAL HEALTH AND NON-MALIGNANT DISEASE (PART I) Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 324 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.S. Prime, M. Davies, M. Pring, and I.C. Paterson THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II) Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Campbell, V. Bovenzi, and M. Szyf Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo Carcinogenesis, April 1, 2004; 25(4): 499 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Velasco-Loyden, J. Arribas, and F. Lopez-Casillas The Shedding of Betaglycan Is Regulated by Pervanadate and Mediated by Membrane Type Matrix Metalloprotease-1 J. Biol. Chem., February 27, 2004; 279(9): 7721 - 7733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lopez-Casillas, C. Riquelme, Y. Perez-Kato, M. V. Ponce-Castaneda, N. Osses, J. Esparza-Lopez, G. Gonzalez-Nunez, C. Cabello-Verrugio, V. Mendoza, V. Troncoso, et al. Betaglycan Expression Is Transcriptionally Up-regulated during Skeletal Muscle Differentiation. CLONING OF MURINE BETAGLYCAN GENE PROMOTER AND ITS MODULATION BY MyoD, RETINOIC ACID, AND TRANSFORMING GROWTH FACTOR-beta J. Biol. Chem., January 3, 2003; 278(1): 382 - 390. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
